Journal
ONCOTARGETS AND THERAPY
Volume 5, Issue -, Pages 391-401Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S38403
Keywords
beta-adrenergic signaling; cancer; beta-blockers; progression; metastasis; angiogenesis
Categories
Funding
- National Natural Science Foundation of China [81071903, 81072069]
- Key Clinical Discipline of the Ministry of Health [201043941]
- Mingdao Project of Fudan University
Ask authors/readers for more resources
beta-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that beta-adrenergic antagonists, or beta-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, migration, invasion, resistance to programmed cell death, and tumor angiogenesis and metastasis. Human pharmacoepidemiologic studies suggest that beta-blockers have a role in inhibiting cancer progression and metastasis in combination with standard therapies. Furthermore, a number of prospective studies have demonstrated that beta-blockers are effective at halting infantile hemangioma growth. These findings shed light on the novel perspective of using beta-blockers as a class of potential antitumor agents in clinical oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available